NCT06873581 (ARID II) is a Phase 3 clinical trial of Voro Urologic Scaffold in Radical Prostatectomy, sponsored by Levee Medical, Inc..

Who is sponsoring NCT06873581?

NCT06873581 is sponsored by Levee Medical, Inc..

What drugs are being tested in NCT06873581?

Interventions in NCT06873581: Voro Urologic Scaffold.

What condition does NCT06873581 study?

NCT06873581 studies Radical Prostatectomy, Stress Urinary Incontinence (SUI).

Is NCT06873581 still recruiting?

NCT06873581 is currently recruiting now. Last updated 30 March 2026.

Last reviewed 2026-03-30 · How we verify

NCT06873581: ARID II

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pivotal Study of Voro Urologic Scaffold

Recruiting now Phase 3 Last updated 30 March 2026

What this trial tests

Phase 3 trial testing Voro Urologic Scaffold in Radical Prostatectomy in 266 participants. Currently enrolling.

Timeline

18 April 2025

Primary endpoint
1 February 2027

1 February 2028

Quick facts

Lead sponsor	Levee Medical, Inc.
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	266
Start date	18 April 2025
Primary completion	1 February 2027
Estimated completion	1 February 2028
Sites	20 locations across United States

Drugs / interventions tested

Voro Urologic Scaffold

Conditions studied

Radical Prostatectomy — all drugs for Radical Prostatectomy →
Stress Urinary Incontinence (SUI) — all drugs for Stress Urinary Incontinence (SUI) →

Sponsor

Levee Medical, Inc. — full company profile →

Who can join

45 and older, male only, with Radical Prostatectomy or Stress Urinary Incontinence (SUI). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to compare safety and effectiveness of the Voro Urologic Scaffold in adult men undergoing robotic assisted radical prostatectomy as compared to control arm. The study is a multi-center, single blind, randomized, controlled trial. Up to 266 participants will be treated at up to 30 centers in the United States. The study will consist of a Baseline visit, implantation during robotic assisted radical prostatectomy (RARP), catheter removal, 6 weeks, 6 months, 12 months, 18 months, and 24 months.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Initial results with an absorbable urologic scaffold to mitigate early urinary incontinence following radical prostatectomy: the ARID study.
Gahan JC, Espino G, Young M, Bodden E, et al · · 2026 · PMID 41546699 · DOI 10.1007/s00345-026-06186-7

Verify or expand the search:

Other trials of Voro Urologic Scaffold

Trials testing the same drug.

NCT06275945 — Feasibility Study of A VoRo UrologIc ScaffolD (ARID) · Phase 2 · active not recruiting

Other recruiting trials for Radical Prostatectomy

Currently open trials in the same condition.

NCT07426861 — Pre-Operative Nurse-Led Education With Direct Physiotherapy Referral to Reduce Post-Prostatectomy Incontinence · NA · recruiting
NCT06085664 — A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed · Phase 1, PHASE2 · recruiting
NCT05558007 — Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients · Phase 2 · recruiting
NCT06275945 — Feasibility Study of A VoRo UrologIc ScaffolD (ARID) · Phase 2 · active not recruiting
NCT04687969 — Multimodal Machine Learning Characterization of Solid Tumors · active not recruiting

Other Levee Medical, Inc. trials

Trials by the same sponsor.

NCT06275945 — Feasibility Study of A VoRo UrologIc ScaffolD (ARID) · Phase 2 · active not recruiting
NCT06351579 — Data Collection Post Radical Prostatectomy · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06873581 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Levee Medical, Inc.
Last refreshed: 30 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06873581.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing